Table 1 Baseline characteristics of study participants

Baseline characteristics including outliers (all randomizedpatients)

n

33

32

Female proportion [n (%)]

11 (33.3%)

10 (31.2%)

0.534

Mean age in years [mean (SD)]

10.0 (3.1)

10.6 (2.9)

0.403

GINA level 2 [n (%)]

26 (78.8%)

26 (81.2%)

0.525

GINA level 3 [n (%)]

7 (21.2%)

6 (18.8%)

Mean peak flow in l/min [mean (SD)]

296 (101)

315 (91)

0.444

Mean annual costs for allergic-drugs before intervention onset in euro[mean (SD)]

434 (332)

296 (220)

0.130

Mean annual costs for non-allergic-drugs before intervention onset ineuro [mean (SD)]

51 (87)

50 (98)

0.571

Mean total annual drug costs before intervention onset in euro [mean(SD)]

485 (377)

345 (245)

0.083

Baseline characteristics without outliers (all analysedpatients)

n

28

31

Female proportion [n (%)]

8 (28.6%)

10 (32.3%)

0.785

Mean age in years [mean (SD)]

10.4 (3.2)

10.8 (2.8)

0.628

GINA level 2 [n (%)]

21 (75.0%)

25 (80.6%)

0.417

GINA level 3 [n (%)]

7 (25.0%)

6 (19.4%)

Mean asthma level GINA [mean (SD)]

2.25 (0.441)

2.19 (0.402)

0.755

Mean peak flow in l/min [mean (SD)]

308 (105)

317 (91)

0.727

Mean annual costs for allergic-drugs before intervention onset in euro[mean (SD)]

315 (180)

273 (183)

0.443

Mean annual costs for non-allergic-drugs before intervention onset ineuro [mean (SD)]

33 (54)

48 (99)

0.974

Mean total annual drug costs before intervention onset in euro [mean(SD)]

349 (192)

322 (209)

0.627